AUTL earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -1.32. Updated 2026-07-23.
Autolus Therapeutics (AUTL) Research Hub
Autolus Therapeutics (AUTL) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.88 USD (-7.39%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.32, market cap 0.38B. This hub links to the full technical, earnings and options research available for AUTL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 1.88 USD (-7.39%) |
| 52-week range | 1.39 USD – 2.58 USD |
| Trend regime | Range |
| 14-day RSI | 41.7 (Bearish) |
| Trailing P/E | -1.32 |
| Market cap | 0.38B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for AUTL
Covered Call on AUTL: how it works, illustrative setup around the real 1.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AUTL: how it works, illustrative setup around the real 1.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AUTL: how it works, illustrative setup around the real 1.88 USD price, max profit/loss, breakeven and when to use it. Educational.
AUTL technical analysis: range, last 1.88 USD, RSI 41.7, 52w range 1.39 USD–2.58 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AUTL in?
Autolus Therapeutics (AUTL) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is AUTL in an uptrend or downtrend?
As of 2026-09-11, AUTL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AUTL's trailing P/E ratio?
AUTL's trailing P/E is -1.32, with a market cap of 0.38B. See the earnings research page for full valuation detail.
When does AUTL next report earnings?
AUTL is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.22 USD.